JP2023182694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023182694A5 JP2023182694A5 JP2023169299A JP2023169299A JP2023182694A5 JP 2023182694 A5 JP2023182694 A5 JP 2023182694A5 JP 2023169299 A JP2023169299 A JP 2023169299A JP 2023169299 A JP2023169299 A JP 2023169299A JP 2023182694 A5 JP2023182694 A5 JP 2023182694A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- independently selected
- cycloalkyl
- occurrence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 229910020008 S(O) Inorganic materials 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 7
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002140 halogenating effect Effects 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000002524 organometallic group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- CUBOHHUXNUJLPW-MRXNPFEDSA-N 4-amino-7-[(1R)-1-[1-(2,4-difluorophenyl)pyrazol-4-yl]propyl]-5-[2-(trifluoromethyl)pyrimidin-5-yl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)(F)F)C#N)[C@H](CC)C=1C=NN(C=1)C1=C(C=C(C=C1)F)F CUBOHHUXNUJLPW-MRXNPFEDSA-N 0.000 claims 1
- WFQPDEQEYIJFND-MRXNPFEDSA-N 4-amino-7-[(1R)-1-[1-(2-fluorophenyl)pyrazol-4-yl]propyl]-5-[2-(trifluoromethyl)pyrimidin-5-yl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)(F)F)C#N)[C@H](CC)C=1C=NN(C=1)C1=C(C=CC=C1)F WFQPDEQEYIJFND-MRXNPFEDSA-N 0.000 claims 1
- AGIUHPGELICMKB-NSHDSACASA-N 4-amino-7-[(1S)-1-[1-(2,4-difluorophenyl)pyrazol-4-yl]ethyl]-5-[2-(trifluoromethyl)pyrimidin-5-yl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)(F)F)C#N)[C@@H](C)C=1C=NN(C=1)C1=C(C=C(C=C1)F)F AGIUHPGELICMKB-NSHDSACASA-N 0.000 claims 1
- CUBOHHUXNUJLPW-INIZCTEOSA-N 4-amino-7-[(1S)-1-[1-(2,4-difluorophenyl)pyrazol-4-yl]propyl]-5-[2-(trifluoromethyl)pyrimidin-5-yl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)(F)F)C#N)[C@@H](CC)C=1C=NN(C=1)C1=C(C=C(C=C1)F)F CUBOHHUXNUJLPW-INIZCTEOSA-N 0.000 claims 1
- IHGAYQLRXCKUOT-HNNXBMFYSA-N 4-amino-7-[(1S)-1-[1-(2,4-difluorophenyl)triazol-4-yl]propyl]-5-[2-(trifluoromethyl)pyrimidin-5-yl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)(F)F)C#N)[C@@H](CC)C=1N=NN(C=1)C1=C(C=C(C=C1)F)F IHGAYQLRXCKUOT-HNNXBMFYSA-N 0.000 claims 1
- CHXHEGXJAHWODR-LBPRGKRZSA-N 4-amino-7-[(1S)-1-[1-(2-fluorophenyl)pyrazol-4-yl]ethyl]-5-[2-(trifluoromethyl)pyrimidin-5-yl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)(F)F)C#N)[C@@H](C)C=1C=NN(C=1)C1=C(C=CC=C1)F CHXHEGXJAHWODR-LBPRGKRZSA-N 0.000 claims 1
- WFQPDEQEYIJFND-INIZCTEOSA-N 4-amino-7-[(1S)-1-[1-(2-fluorophenyl)pyrazol-4-yl]propyl]-5-[2-(trifluoromethyl)pyrimidin-5-yl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)(F)F)C#N)[C@@H](CC)C=1C=NN(C=1)C1=C(C=CC=C1)F WFQPDEQEYIJFND-INIZCTEOSA-N 0.000 claims 1
- RMCWKPZLCSJNDN-UHFFFAOYSA-N 4-amino-7-[[1-(2,4-difluorophenyl)pyrazol-4-yl]methyl]-5-[2-(trifluoromethyl)pyrimidin-5-yl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)(F)F)C#N)CC=1C=NN(C=1)C1=C(C=C(C=C1)F)F RMCWKPZLCSJNDN-UHFFFAOYSA-N 0.000 claims 1
- LSTMAJPRFFZYIT-UHFFFAOYSA-N 4-amino-7-[[1-(2-fluorophenyl)pyrazol-4-yl]methyl]-5-[2-(trifluoromethyl)pyrimidin-5-yl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C=1C=NC(=NC=1)C(F)(F)F)C#N)CC=1C=NN(C=1)C1=C(C=CC=C1)F LSTMAJPRFFZYIT-UHFFFAOYSA-N 0.000 claims 1
- -1 C1 -C6 alkyl Chemical group 0.000 claims 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical group BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423919P | 2016-11-18 | 2016-11-18 | |
| US62/423,919 | 2016-11-18 | ||
| PCT/US2017/062148 WO2018094137A1 (en) | 2016-11-18 | 2017-11-17 | Pyrrolopyrimidines as cftr potentiators |
| JP2019547579A JP6978507B2 (ja) | 2016-11-18 | 2017-11-17 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
| JP2021183048A JP7360434B2 (ja) | 2016-11-18 | 2021-11-10 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021183048A Division JP7360434B2 (ja) | 2016-11-18 | 2021-11-10 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023182694A JP2023182694A (ja) | 2023-12-26 |
| JP2023182694A5 true JP2023182694A5 (https=) | 2024-04-10 |
| JP7592814B2 JP7592814B2 (ja) | 2024-12-02 |
Family
ID=62144793
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547579A Active JP6978507B2 (ja) | 2016-11-18 | 2017-11-17 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
| JP2021183048A Active JP7360434B2 (ja) | 2016-11-18 | 2021-11-10 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
| JP2023169299A Active JP7592814B2 (ja) | 2016-11-18 | 2023-09-29 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547579A Active JP6978507B2 (ja) | 2016-11-18 | 2017-11-17 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
| JP2021183048A Active JP7360434B2 (ja) | 2016-11-18 | 2021-11-10 | Ｃｆｔｒ増強物質としてのピロロピリミジン |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10301315B2 (https=) |
| EP (2) | EP3541390B1 (https=) |
| JP (3) | JP6978507B2 (https=) |
| KR (2) | KR102585398B1 (https=) |
| CN (2) | CN110337294B (https=) |
| AU (2) | AU2017362350B2 (https=) |
| CL (1) | CL2019001334A1 (https=) |
| CO (1) | CO2019005993A2 (https=) |
| CR (1) | CR20190292A (https=) |
| DO (1) | DOP2019000126A (https=) |
| EC (1) | ECSP19043120A (https=) |
| ES (1) | ES2983686T3 (https=) |
| IL (3) | IL314404B2 (https=) |
| MX (2) | MX2021012639A (https=) |
| PE (1) | PE20200739A1 (https=) |
| PH (1) | PH12019501098A1 (https=) |
| PL (1) | PL3541390T3 (https=) |
| RU (2) | RU2757457C2 (https=) |
| SG (1) | SG10202106949XA (https=) |
| UA (1) | UA125400C2 (https=) |
| WO (1) | WO2018094137A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9487495B2 (en) | 2012-01-06 | 2016-11-08 | The Scripts Research Institute | Carbamate compounds and of making and using same |
| TWI735416B (zh) | 2014-10-06 | 2021-08-11 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| MA44126A (fr) * | 2015-12-22 | 2018-10-31 | Proteostasis Therapeutics Inc | Méthodes de traitement de maladies et troubles pulmonaires |
| SI3519401T1 (sl) | 2016-09-30 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja |
| AU2017362350B2 (en) | 2016-11-18 | 2021-12-23 | Cystic Fibrosis Foundation | Pyrrolopyrimidines as CFTR potentiators |
| CN110267948B (zh) | 2016-12-09 | 2023-12-08 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法 |
| US10131670B2 (en) | 2016-12-16 | 2018-11-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Bicyclic heteroaryl derivatives as CFTR potentiators |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| KR102716244B1 (ko) | 2017-12-08 | 2024-10-14 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| AU2019222758B2 (en) | 2018-02-15 | 2022-07-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| AU2020290094B2 (en) * | 2019-06-10 | 2024-01-18 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis |
| BR112022000507A2 (pt) | 2019-07-15 | 2022-05-10 | Novartis Ag | Formulações de (s)-3-amino-6-metóxi-n-(3,3,3-trifluoro-2-hidróxi-2-metilpropil)-5-(trifluorometil)picolinamida |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| CA3150162A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| CN111138439B (zh) * | 2020-01-17 | 2021-06-25 | 厦门大学 | 氟代吡咯并嘧啶类化合物及其制备方法和应用 |
| WO2021176049A1 (en) | 2020-03-06 | 2021-09-10 | Bayer Aktiengesellschaft | Pyrazolopyrazines acting on cancers via inhibition of cdk12 |
| IL300413A (en) | 2020-08-13 | 2023-04-01 | Vertex Pharma | Crystal forms of CFTR modulators |
| KR20230052954A (ko) | 2020-08-20 | 2023-04-20 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법 |
| EP4225762A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| AU2021397294A1 (en) | 2020-12-10 | 2023-07-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| TW202425990A (zh) * | 2022-11-02 | 2024-07-01 | 南韓商日東製藥股份有限公司 | 包含ｃｆｔｒ調節劑化合物之點眼用組成物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19990067704A (ko) * | 1992-12-17 | 1999-08-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물 |
| US5869485A (en) | 1994-09-29 | 1999-02-09 | Novartis Finance Corp. | Pyrrolo 2,3-d!pyrimidines and their use |
| ID29028A (id) | 1998-09-18 | 2001-07-26 | Basf Ag | Pirolopirimidina sebagai penghambat protein kinase |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| WO2002096867A2 (en) | 2001-05-30 | 2002-12-05 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| DE10135815A1 (de) | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| WO2004100868A2 (en) * | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
| US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| EP1913000B1 (en) | 2005-07-29 | 2012-01-11 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis |
| WO2007064931A2 (en) | 2005-12-02 | 2007-06-07 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| ES2545907T3 (es) * | 2005-12-29 | 2015-09-16 | Abbvie Inc. | Inhibidores de proteína quinasa |
| EA200801968A1 (ru) * | 2006-03-11 | 2009-02-27 | Вернэлис (Р&Д) Лтд. | Пирролопиримидиновые производные, используемые в качестве ингибиторов hsp90 |
| WO2007114926A2 (en) * | 2006-04-04 | 2007-10-11 | The Regents Of The University Of California | Kinase antagonists |
| CA2705303A1 (en) * | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| EA024252B1 (ru) | 2009-01-08 | 2016-08-31 | Кьюрис, Инк. | Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой |
| US20130035325A1 (en) | 2009-11-16 | 2013-02-07 | The Regents Of The University Of California | Kinase inhibitors |
| CN102770133A (zh) | 2010-02-05 | 2012-11-07 | 拜耳知识产权有限责任公司 | 用于治疗囊性纤维化的单独和与PDE5抑制剂组合的sGC刺激剂或sGC激活剂 |
| WO2013071232A1 (en) | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules |
| UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| WO2014060431A1 (en) * | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| CN105431437B (zh) | 2013-07-02 | 2020-03-10 | 理森制药股份公司 | PI3K蛋白激酶抑制剂，特别是δ抑制剂和/或γ抑制剂 |
| WO2015091532A1 (en) * | 2013-12-19 | 2015-06-25 | Almirall, S.A. | Pyrrolopyrimidine derivatives as pi3k inhibitors |
| TWI735416B (zh) | 2014-10-06 | 2021-08-11 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| AU2017362350B2 (en) | 2016-11-18 | 2021-12-23 | Cystic Fibrosis Foundation | Pyrrolopyrimidines as CFTR potentiators |
| US10131670B2 (en) | 2016-12-16 | 2018-11-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Bicyclic heteroaryl derivatives as CFTR potentiators |
-
2017
- 2017-11-17 AU AU2017362350A patent/AU2017362350B2/en active Active
- 2017-11-17 IL IL314404A patent/IL314404B2/en unknown
- 2017-11-17 IL IL296279A patent/IL296279A/en unknown
- 2017-11-17 MX MX2021012639A patent/MX2021012639A/es unknown
- 2017-11-17 MX MX2019005822A patent/MX387203B/es unknown
- 2017-11-17 KR KR1020197017510A patent/KR102585398B1/ko active Active
- 2017-11-17 JP JP2019547579A patent/JP6978507B2/ja active Active
- 2017-11-17 RU RU2019118623A patent/RU2757457C2/ru active
- 2017-11-17 US US15/815,809 patent/US10301315B2/en active Active
- 2017-11-17 EP EP17872726.9A patent/EP3541390B1/en active Active
- 2017-11-17 CR CR20190292A patent/CR20190292A/es unknown
- 2017-11-17 PE PE2019001045A patent/PE20200739A1/es unknown
- 2017-11-17 ES ES17872726T patent/ES2983686T3/es active Active
- 2017-11-17 SG SG10202106949XA patent/SG10202106949XA/en unknown
- 2017-11-17 CN CN201780083801.0A patent/CN110337294B/zh active Active
- 2017-11-17 UA UAA201906838A patent/UA125400C2/uk unknown
- 2017-11-17 RU RU2021129721A patent/RU2021129721A/ru unknown
- 2017-11-17 PL PL17872726.9T patent/PL3541390T3/pl unknown
- 2017-11-17 EP EP24170395.8A patent/EP4424311A3/en active Pending
- 2017-11-17 WO PCT/US2017/062148 patent/WO2018094137A1/en not_active Ceased
- 2017-11-17 CN CN202211239693.0A patent/CN115850268B/zh active Active
- 2017-11-17 KR KR1020237033420A patent/KR102824092B1/ko active Active
-
2019
- 2019-04-05 US US16/377,005 patent/US10494374B2/en active Active
- 2019-05-15 IL IL266668A patent/IL266668B2/en unknown
- 2019-05-16 PH PH12019501098A patent/PH12019501098A1/en unknown
- 2019-05-16 CL CL2019001334A patent/CL2019001334A1/es unknown
- 2019-05-17 DO DO2019000126A patent/DOP2019000126A/es unknown
- 2019-06-07 CO CONC2019/0005993A patent/CO2019005993A2/es unknown
- 2019-06-17 EC ECSENADI201943120A patent/ECSP19043120A/es unknown
- 2019-09-20 US US16/578,277 patent/US20200017512A1/en not_active Abandoned
-
2021
- 2021-02-18 US US17/179,062 patent/US20210171534A1/en not_active Abandoned
- 2021-11-10 JP JP2021183048A patent/JP7360434B2/ja active Active
-
2022
- 2022-03-16 AU AU2022201816A patent/AU2022201816B2/en active Active
-
2023
- 2023-04-13 US US18/134,455 patent/US12612409B2/en active Active
- 2023-09-29 JP JP2023169299A patent/JP7592814B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023182694A5 (https=) | ||
| JP2021523221A5 (https=) | ||
| Janin | Preparation and chemistry of 3/5-halogenopyrazoles | |
| RU2021129721A (ru) | Пирролопиримидины в качестве потенциаторов мвтр | |
| HRP20240513T1 (hr) | Derivati pirazolila korisni kao sredstva protiv raka | |
| RU2003105805A (ru) | Производные 4-фенилпиридина в качестве антагонистов рецепторов нейрокинина-1 | |
| ES2543904T9 (es) | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus | |
| RU2015138964A (ru) | Полициклические модуляторы рецептора эстрогена и их применения | |
| JP2018524331A5 (https=) | ||
| JP2023521351A5 (https=) | ||
| RU2018102372A (ru) | Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их | |
| HRP20211778T1 (hr) | Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina | |
| JP2016537389A5 (https=) | ||
| JP2017504576A5 (https=) | ||
| SI2743266T1 (en) | Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis | |
| JP2022550640A5 (https=) | ||
| JP2016535772A5 (https=) | ||
| RU2016123449A (ru) | Октагидро конденсированные азадекалиновые модуляторы глюкокортикоидного рецептора | |
| JP2022523154A5 (https=) | ||
| JP2021500340A5 (https=) | ||
| JP2022017461A5 (https=) | ||
| JP2022553841A5 (https=) | ||
| JP2006508192A5 (https=) | ||
| JP2025503448A5 (https=) | ||
| HRP20241225T1 (hr) | Inhibitori p300/cbp hat |